Dabomb Protein Biotech (ROCO:6578) Research & Development: NT$16.2 Mil (TTM As of Dec. 2025)


ROCO:6578 Dabomb Protein Biotech Corp ROCO:6578
61 GF Score
Price NT$16.25
GF Value NT$14.62
Valuation Modestly Overvalued
! 1 Warning Sign
View Full Analysis

What is Dabomb Protein Biotech Research & Development?

Dabomb Protein Biotech ROCO:6578 +0.93% 61 Research & Development is NT$16.2 Mil as of Dec. 2025. GuruFocus rates ROCO:6578 with a GF Score™ of 61/100 and a GF Value™ of NT$14.62 (Modestly Overvalued). The stock has 1 warning sign investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Dabomb Protein Biotech's Research & Development for the three months ended in Dec. 2025 was NT$3.0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was NT$16.2 Mil.

Dabomb Protein Biotech  (ROCO:6578) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Dabomb Protein Biotech Research & Development Related Terms

Dabomb Protein Biotech Research & Development Historical Data

* Premium members only.

The historical data trend for Dabomb Protein Biotech's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Dabomb Protein Biotech Research & Development Chart

Dabomb Protein Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.82 11.85 13.59 14.95 16.23

Dabomb Protein Biotech Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.56 4.71 3.94 4.61 2.97
ROCO:6578
61GF Score
Dabomb Protein Biotech Corp ROCO:6578
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Dabomb Protein Biotech Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$16.2 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of NT$16.2 Mil mean?
Dabomb Protein Biotech (ROCO:6578) has a Research & Development of NT$16.2 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Dabomb Protein Biotech and its competitors.
Is Dabomb Protein Biotech's Research & Development too high?
Dabomb Protein Biotech's current Research & Development is NT$16.2 Mil. Overall, Dabomb Protein Biotech has a GF Score™ of 61/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Dabomb Protein Biotech's Research & Development compare to KHC and GIS?
Dabomb Protein Biotech's Research & Development of NT$16.2 Mil can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Consumer Packaged Goods company?
A good Research & Development depends on the Consumer Packaged Goods industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Dabomb Protein Biotech and its competitors. Dabomb Protein Biotech's current Research & Development is NT$16.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Dabomb Protein Biotech stock overvalued right now?
Based on GuruFocus' analysis, Dabomb Protein Biotech (ROCO:6578) is currently considered Modestly Overvalued. The stock's GF Value™ is NT$14.62, compared to a current price of NT$16.25 — trading 11.1% above its estimated fair value. The current Research & Development is NT$16.2 Mil. Dabomb Protein Biotech's overall GF Score™ is 61/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Dabomb Protein Biotech (ROCO:6578), the current Research & Development is NT$16.2 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Dabomb Protein Biotech (ROCO:6578) Overvalued in 2026?

Based on GuruFocus' analysis, Dabomb Protein Biotech stock appears to be overvalued. The current stock price of NT$16.25 is trading 11.1% above its estimated GF Value™ of NT$14.62. GuruFocus considers Dabomb Protein Biotech to be Modestly Overvalued.

Key valuation signals for ROCO:6578:

  • Research & Development: NT$16.2 Mil
  • GF Value™: NT$14.62 vs. price of NT$16.25 (11.1% above fair value)
  • GF Score™: 61/100 with 1 warning sign

No single metric tells the full story. See the ROCO:6578 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Dabomb Protein Biotech Business Description

Address No. 52, Industrial 3rd Road, Annan District, Tainan, TWN, 709
Dabomb Protein Biotech Corp is engaged in the manufacture, wholesale, and sale of hydrolyzed soy protein. The products of the company include Plant protein, Antibiotics alternatives, Pet care, Core technology, and CDMO(ODM/OEM). The company operates in a single segment engaged in the manufacture, wholesale and sales of hydrolysed soy protein. Geographically it operates in Malaysia, Taiwan, USA, Vietnam, and Others with majority of the revenue deriving from Vietnam.
61GF Score

Get the complete analysis for ROCO:6578

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$16.25
Price
NT$14.62
GF Value